Disclosures for "Long-term Safety and Sustained Functional Benefit in Patients with Duchenne Muscular Dystrophy (DMD) 4 Years Post-Treatment with Delandistrogene Moxeparvovec (SRP-9001) in a Phase 1/2a Study")
-
Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received research support from Sarepta.
-
Dr. Sahenk has nothing to disclose.
-
Ms. Lehman has nothing to disclose.
-
The institution of Ms. Lowes has received research support from Sarepta Therapeutics.
-
Dr. Reash has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ATOM International. Dr. Reash has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Casimir, LLC. The institution of Dr. Reash has received research support from Sarepta. Dr. Reash has received intellectual property interests from a discovery or technology relating to health care. Dr. Reash has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Iammarino has received personal compensation in the range of $0-$499 for serving as a Consultant for Genentech.
-
Ms. Alfano has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ATOM International, Ltd (Amicus Therapeutics, Catabasis, Genethon, Italfarmaco, NS Pharma, Pfizer, PTC Therapeutics). Ms. Alfano has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Novartis Gene Therapies. The institution of Ms. Alfano has received research support from Sarepta Therapeutics. The institution of Ms. Alfano has received research support from Audentes Therapeutics/Astellas Gene Therapies. Ms. Alfano has received intellectual property interests from a discovery or technology relating to health care.
-
Sarah Lewis has received stock or an ownership interest from Sarepta.
-
Kathleen Church has nothing to disclose.
-
Richard Shell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avexis. Richard Shell has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen.
-
Rachael Potter has received stock or an ownership interest from Sarepta Therapeutics.
-
Ms. Griffin has stock in Sarepta Therapeutics. Ms. Griffin has received intellectual property interests from a discovery or technology relating to health care.
-
Mark Hogan has nothing to disclose.
-
Shufang Wang has received personal compensation for serving as an employee of Sarepta Therapeutics INC. Shufang Wang has received stock or an ownership interest from Sarepta Therapeutics INC.
-
Dr. Mason has received personal compensation for serving as an employee of Sarepta. Dr. Mason has stock in Sarepta. An immediate family member of Dr. Mason has stock in Sarepta. The institution of an immediate family member of Dr. Mason has received research support from Biogen. The institution of Dr. Mason has received research support from NIH. The institution of Dr. Mason has received research support from Chest Foundation.
-
Dr. Darton has received personal compensation for serving as an employee of Sarepta Therapeutics. Dr. Darton has stock in Sarepta Therapeutics.
-
Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care.